In 2 cross-sectional studies, plasma β-amyloid 42 to β-amyloid 40 ratio, measured using immunoassay, accurately predicted cerebral β-amyloid status in all stages of Alzheimer disease in the BioFINDER cohort (n = 842) and in an independent validation cohort (n = 237). This evidence concerns the gene PPIB and Alzheimer disease.